Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes

Emanuele Monda 1†, Marta Rubino 1†, Michele Lioncino 1, Francesco Di Fraia 1, Roberta Pacileo 1, Federica Verrillo 1, Annapaola Cirillo 1, Martina Caiazza 1, Adelaide Fusco 1, Augusto Esposito 1, Fabio Fimiani 1, Giuseppe Palmiero 1, Giuseppe Pacileo 1, Paolo Calabro 1, Maria Giovanna Russo 1 and Giuseppe Limongelli 1,2*

1 Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy, 2 Institute of Cardiovascular Sciences, University College of London and St. Bartholomew’s Hospital, London, United Kingdom

Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular hypertrophy not solely explained by abnormal loading conditions. Despite its rare prevalence in pediatric age, HCM carries a relevant risk of mortality and morbidity in both infants and children. Pediatric HCM is a large heterogeneous group of disorders. Other than mutations in sarcomeric genes, which represent the most important cause of HCM in adults, childhood HCM includes a high prevalence of non-sarcomeric causes, including inherited errors of metabolism (i.e., glycogen storage diseases, lysosomal storage diseases, and fatty acid oxidation disorders), malformation syndromes, neuromuscular diseases, and mitochondrial disease, which globally represent up to 35% of children with HCM. The age of presentation and the underlying etiology significantly impact the prognosis of children with HCM. Moreover, in recent years, different targeted approaches for non-sarcomeric etiologies of HCM have emerged. Therefore, the etiological diagnosis is a fundamental step in designing specific management and therapy in these subjects. The present review aims to provide an overview of the non-sarcomeric causes of HCM in children, focusing on the pathophysiology, clinical features, diagnosis, and treatment of these rare disorders.

Keywords: hypertrophic cardiomyopathy, etiology, children, diagnosis, treatment

INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by left ventricular (LV) hypertrophy not solely explained by abnormal loading conditions (1). HCM is a common genetic disorder in adults, with an estimated prevalence of 1:500 (1); on the contrary, it is rare in children but carries an important risk of morbidity and mortality (2). Compared with adult HCM, pediatric HCM is a more heterogeneous group of disorders. Other than mutations in sarcomeric genes, which represent the most important cause of HCM both in adults and in children (40–60% of cases) (1–7), the other causes of HCM include inherited errors of metabolism (i.e., glycogen storage diseases (GSDs), lysosomal storage diseases, and fatty acid oxidation disorders), neuromuscular diseases, malformation syndromes (i.e., RASopathies), and mitochondrial disease (Table 1), which
TABLE 1 | Causes of hypertrophic cardiomyopathy in children.

| Sarcomeric                          | Malformation syndromes: RASopathies                  | Glycogen storage diseases | Lysosomal storage diseases | Mitochondrial disorders | Fatty acid oxidation disorders | Endocrine disorders |
|-------------------------------------|------------------------------------------------------|---------------------------|---------------------------|-------------------------|-------------------------------|--------------------|
| Noonan syndrome                     | Noonan syndrome                                      | Pompe disease             | Mucopolysaccharidoses     | Very long-chain acyl-CoA  | Primary hyperinsulinism       | Infant of a mother   |
| Noonan syndrome with multiple       | Noonan syndrome with multiple lentigines             | (glycogen storage         | Mitochondrial disorders   | dehydrogenase deficiency   | Hypertension in diabetes    | with diabetes       |
| lentigines                          | Costello syndrome                                    | disease type IIA)         |                           |                         | mellitus                      | mellitus            |
| Cardiofaciocutaneous syndrome       |                                                     | Danon disease             |                           |                         |                               |                    |
|   |                                                     | (glycogen storage         |                           |                         |                               |                    |
|   |                                                     | disease type IIB)         |                           |                         |                               |                    |
|   |                                                     | Cori–Forbes disease      |                           |                           |                               |                    |
|   |                                                     | (glycogen storage         |                           |                         |                               |                    |
|   |                                                     | disease type III)         |                           |                         |                               |                    |
|   |                                                     | PRKAG2 syndrome          |                           |                         |                               |                    |
|   |                                                     |                           |                           |                         |                               |                    |

globally represent up to 35% of children with HCM (2, 8). Sometimes, HCM is a feature of genetic syndromes associated with congenital heart disease (CHD), such as Noonan syndrome (NS), in which, for example, valvular pulmonary stenosis and HCM can be associated (3).

According to the 2020 American Heart Association/American College of Cardiology (AHA/ACC) guidelines, diagnosis of sarcomeric HCM in children requires an LV wall thickness more than 2 standard deviations from the predicted mean in children with a positive family history or a positive genetic test, and more than 2.5 in those without (9); however, specific z score thresholds have not been independently standardized.

The latest classification of cardiomyopathies in children of the AHA (10) has classified HCM in primary HCM, if a mutation in sarcomeric genes represents the cause of the disorder, and secondary HCM, if the disorder is associated with a non-sarcomeric cause; for the purpose of this document, we will refer to this classification.

In non-sarcomeric HCM, although the increased LV wall thickness can simulate that of sarcomeric form, the pathophysiology, the natural history, and the treatment are different. Thus, in subjects who meet the threshold for HCM diagnosis, causal predisposition or addition phenotypic characteristics need to be evaluated to identify the underlying cause (1, 3, 10, 11). To early identify the etiology of HCM, several diagnostic markers (obtained by pedigree analysis, physical examination, electrocardiography, echocardiography, and laboratory tests), the so-called “red flags,” have been recommended to guide specialized diagnostic testing, including genetic analysis (1, 3, 10, 11) (Figures 1, 2). The age of presentation can be considered a “red flag” for specific causes of HCM and also has a prognostic role. For example, HCM presenting before 1 year of age shows a worse prognosis (2) and is principally caused by inherited errors of metabolism or malformation syndrome (e.g., RASopathies) (Figure 3). On the contrary, mutations in sarcomeric genes represent the most important causes of HCM outside infancy, with a better prognosis compared with non-sarcomeric forms of HCM (2, 12, 13).

In recent years, several targeted approaches for specific etiologies of HCM have emerged (14, 15). Thus, the etiological diagnosis of HCM in children is a fundamental step in designing specific management and therapy in these subjects. The present review aims to provide an overview of the specific causes of HCM in children, focusing on the pathophysiology, diagnosis, and treatment of these rare disorders.

MALFORMATION SYNDROMES: RASOPATHIES

Introduction

RASopathies are a group of genetic disorders caused by mutations in RAS-MAPK cascade, which constitute, taken together, one of the largest groups of malformation syndromes, with a prevalence of 1:1,000–2,500 children (16–18). They include NS, NS with multiple lentigines (NSML; formerly known as LEOPARD syndrome), Costello syndrome (CS), cardiofaciocutaneous syndrome (CFC), neurofibromatosis type 1 (NF1), and Legius syndrome (LS).

Besides cardiac involvement, these diseases show a common clinical pattern whose major features are craniofacial dysmorphology, hypothonia, neurocognitive impairment, short stature, predisposition to various pediatric cancers, and cutaneous, muscular, and ocular abnormalities (19–21).

Clinical Presentation and Diagnostic Considerations

Noonan Syndrome

NS [Online Mendelian Inheritance in Man (OMIM) code #163950] is a developmental multisystemic disorder transmitted with an autosomal dominant pattern (17), and it is the second most common syndromic cause of CHD after trisomy 21 (22). Patients affected by NS are characterized by specific craniofacial features, including broad forehead, down slanting palpebral fissures, hypertelorism, and low-set ears; almost 10% of them have neurosensorial deafness or auditory deficits in the low-frequency range (17). Short stature is a common manifestation of the syndrome as the puberal grow spurt is usually attenuated (23). Up to 80% of male patients have unilateral or bilateral cryptorchidism (24). Among dermatological abnormalities, hypo- or hyperpigmentation can occur, including café-au-lait spots, keratosis pilaris, or multiple pigmented nevi (25). In most individuals, intelligence is within the normal range;
**Possible Neonatologist Scenario:**

**Infant with LVH and Hypoglycemia**

Possible causes:
- Without Metabolic Acidosis
  - Hyperinsulinism
  - Maternal diabetes
  - Congenital hyperinsulinism (transient or persistent)
  - Insulin-resistance syndromes
- Disorders of fatty acid oxidation

With Metabolic Acidosis
- Glycogen storage disorders
- Mitochondrial disorders

Diagnostic algorithm:
1. Confirm hypoglycemia.
2. Consider checking urine organic acids, beta-hydroxybutyrate, insulin, free fatty acid, lactate.
3. Refer to third level cardiomyopathy centre to confirm the diagnosis and further management.

**Possible Neonatologist or Pediatrician Scenario:**

Infant or Children with
- LVH and Dysmorphisms and/or Cutaneous Abnormalities

Possible causes:
- A. RAS-MAPK disease
  - Noonan Syndrome
  - NSML
  - Costello Syndrome
  - Cardio-facio-cutaneous Syndrome
- B. Other genetic syndrome

- LVH and Neuromuscular Symptoms

Possible causes:
- With Ataxia
  - Friedrich Ataxia

With hypotonia, muscle weakness and/or CPK elevations
- Glycogen storage disorders
- Mitochondrial disorders

Refer to third level cardiomyopathy centre to confirm the diagnosis and further management.

**Possible Pediatrician or Pediatric Cardiologist Scenario:**

Infant or Children with LVH and other

ECG or Echo “Red Flags” (see Figure 2)

Possible causes:
- A. Malformation Syndromes
- B. Metabolic Syndromes
- C. Mitochondrial Diseases
- D. Neuromuscular Syndromes
- E. Endocrine Disorders
- F. Others

Refer to third level cardiomyopathy centre to confirm the diagnosis and further management.

---

**FIGURE 1** | Possible scenarios in clinical practice. LVH, left ventricular hypertrophy; NSML, Noonan syndrome with multiple lentigines.

**FIGURE 2** | Diagnostic approach for the infant and young child with hypertrophic cardiomyopathy. AD, autosomal dominant; AR, autosomal recessive; AV, atrioventricular; LVH, left ventricular hypertrophy.
nonetheless, Roelofs et al. showed that almost 60% of the individuals have a significant difference between verbal and non-verbal intelligence quotient (26). Several malignancies have been reported in patients with NS, particularly juvenile myelomonocytic leukemia, acute myelogenous leukemia, and embryonal rhabdomyosarcoma (27).

The first NS pathogenetic gene was described in 2001 by Tartaglia et al. and identified as the tyrosine phosphatase PTPN11, whose missense loss-of-function mutations cause overactivation of the RAS-MAPK cascade (28). Subsequent studies showed that PTPN11 accounts for almost 50% of the cases (29) (Table 2). SOS1 mutations represent the second most common cause of NS, accounting for almost 15% of the patients (30). A rare subset of NS patients who show a particular phenotype of loose anagen hair (also known with the eponym of Mazzanti syndrome) is caused by a single mutation is SHOC2, a scaffold protein linking Ras to RAF1 (31). Later studies identified other genes underlying NS, namely, KRAS (32), RAF1 (33), MAP2K1 (34), BRAF (35), NRAS (36), and CBL (37).

Noonan Syndrome With Multiple Lentigines

Among RASopathies, NSML, also known as LEOPARD syndrome (OMIM code #151100), is similar to NS, but it is characterized by multiple lentigines, sensorineural deafness, ocular hypertelorism, abnormal genitalia, and a higher prevalence of HCM and conduction abnormalities (38). Genetic analysis showed that NSML, similar to NS, is caused by different mutations in PTPN11 (39). Rarely, mutations in RAF1 and BRAF, which are more common in CFC, have been identified in NSML (39, 40).

Costello Syndrome

CS (OMIM code #218040) is a genetic syndrome with many overlapping features with NS (19). Differential diagnosis with NS is seldom feasible during infancy and becomes possible only in adult life (41). Both syndromes can present HCM at very infantile onset, but infants with CS have a lesser prevalence of pulmonary stenosis or complex CHD (40–42). Phenotypic features may be apparent in intrauterine life, with polyhydramnios in utero, prematurity, and increased birth weight. Children with CS have coarse facial features, with a prominent forehead, epicanthal folds, and depressed nasal bridge. The skin is soft and redundant with palmar and plantar creases. Almost 72% of CS patients show evidence of cutaneous papilloma, localized especially at the nose. These neoplasms are not common in other RASopathies and could offer a clue for differential diagnosis (19, 42). CS is caused by heterozygous activating mutations in HRAS. More than 80% of CS patients have a p.G12S substitution, which causes reduction of the GTPase activity of HRAS, with subsequent overactivation of the MAPK pathway (43).

Cardiofaciocutaneous Syndrome

Among the rarest RASopathies, CFC (OMIM code #115150) shows many overlapping features with NS and CS, including
TABLE 2 | Clinical manifestations, mutated genes, and classical heart defects with their relative prevalence among different specific causes of pediatric HCM.

| Specific cause | Gene | Clinical features |
|----------------|------|-------------------|
| **RASopathies** | | |
| Noonan syndrome | PTPN11 | PVS (65%), HCM (20–23%), atrioventricular septal defects (10–18%), ASD (10%), VSD (8.5%), PDA (6%), mitral valve abnormalities (2.5%), tetralogy of Fallot (<1%), aortic coarctation (<1%). |
| | SOS1 | |
| | RAF1 | |
| | RIT1 | |
| | SHOC2 | |
| | NRAS | |
| | CBL | |
| Noonan syndrome with multiple lentigines | PTPN11 | HCM (60–85%), biventricular hypertrophy (46%), LVOTO (40%), ventricular tachycardia, conduction abnormalities, mitral valve abnormalities (26–42%), PVS (21%), ASD (6%), atrioventricular septal defects, coronary artery abnormalities. |
| | BRAF | |
| | MAP2K1–MAP2K2: | |
| | KRAS | |
| Costello syndrome | HRAS | HCM (65%), mitral valve abnormalities (100%), PVS (40%), high risk of SCD. |
| Cardiofaciocutaneous syndrome | BRAF1 | HCM (45%), ASD (30%), VSD (7.6%), tetralogy of Fallot (7%). |
| | MAP2K1–MAP2K2: | |
| | KRAS | PVS (40%), mitral valve abnormalities (26%), HCM (20%), ASD (20%), VSD (13%). |
| Glycogen storage disorders | | |
| Pompe disease | GAA | LVH, short PR interval, hypertension, idiochyclic stroke, cerebral artery aneurysms. |
| Danon disease | LAMP2 | Short PR interval (75%), severe concentric LVH, conduction abnormalities. |
| Cori–Forbes disease | AGL | Concentric LVH (40%), biventricular hypertrophy (15%), HF, isolated septal hypertrophy. |
| PRKAG2 syndrome | PRKAG2 | LVH, AV block (45–50%), SVT (38%), sick sinus disease (50%), SCD (10%), syncope. |
| Lysosomal storage disorders | | |
| Hunter syndrome (MPS type 1) | IDUA | LVH, thickening of valve leaflets or papillary muscles, shortening of subvalvular apparatus, systemic hypertension, dilated cardiomyopathy with reduced EF, pulmonary hypertension, coronary artery disease, AV block. |
| Hunter syndrome (MPS type 2) | IDS | LVH, thickening of valve leaflets or papillary muscles, shortening of subvalvular apparatus, systemic hypertension, dilated cardiomyopathy with reduced EF, pulmonary hypertension, coronary artery disease, AV block. |
| Maroteaux–Lamy syndrome (MPS type 6) | ARSB | LVH, thickening of valve leaflets or papillary muscles, shortening of subvalvular apparatus, systemic hypertension, dilated cardiomyopathy with reduced EF, pulmonary hypertension, coronary artery disease, AV block. |
| Mitochondrial disorders | | |
| MELAS syndrome | Mitochondrial genes | HCM (75%), dilated cardiomyopathy (12.5%), pulmonary hypertension (12.5%), stroke-like episodes. |
| MERRF syndrome | Mitochondrial genes | WPW (45–22%), dilated cardiomyopathy (22%), HF (11%). |
| CoQ10 deficiency | COQ4 | HCM, bradydysrhythmia, HF. |
| Barth syndrome | TAX | Left ventricular non compaction, dilated cardiomyopathy, HCM, endocardial fibroelastosis, ventricular arrhythmia, SCD. |
| Friedrich’s ataxia | FTX | HCM (75%), dilated cardiomyopathy, granular sparkling (rare), bundle branch block (15%). |

ASD, atrial septal defect; HCM, hypertrophic cardiomyopathy; HF, heart failure; LVH, left ventricular hypertrophy; LVOTO, left ventricular outflow tract obstruction; PDA, patent ductus arteriosus; PVS, pulmonary valve stenosis; SCD, sudden cardiac death; VSD, ventricular septal defect; WPW, Wolff–Parkinson–White syndrome.

the typical facies, neurocognitive delay, hypotony, and learning disability (20). Differential diagnosis includes the presence of curly hair with sparse eyebrows and eyelashes (44), and neurological and ocular abnormalities like strabismus and nystagmus (45). Unlike CS, the genetic substrate of CFC is heterogeneous, with mutations in *BRAF1* (34), *MAP2K1*, *MAP2K2* (46), and *KRAS* accounting for 80% of the cases.

**Neurofibromatosis Type 1 and Legius Syndrome**

RASopathies also include NF1 (OMIM code #162200) and LS (OMIM code #611431), caused, respectively, by inactivating mutations of *NF1*, which encode for a GTPase activating protein, and SPRED1, which is a negative mediator of RAS-mediated RAF 1 activation. However, HCM is not commonly associated with NF1 and LS.
Hypertrophic Cardiomyopathy in RASopathies

With the exclusion of CHD, HCM is the most common cardiovascular abnormality observed in RASopathies (47, 48). HCM in RASopathies is characterized by a higher grade of ventricular hypertrophy, an increased prevalence, and a more severe pattern of LV outflow tract obstruction (LVOTO) than non-syndromic forms (49). Biventricular involvement is often described, because of the high prevalence of right ventricular hypertrophy (49). Obstructive forms of HCM are not solely explained by the systolic anterior motion of the mitral valve (MV), but other factors, such as accessory fibrous connective tissue causing subaortic stenosis, displacement of the papillary muscles, and anomalous insertion of the MV, have been described (47). The length of MV leaflets and chordal anatomic relationships are different compared with MV in non-syndromic subjects with HCM (50). To date, MV anomalies are a marker of complexity in HCM and have been associated with a high risk of reintervention and death (51). Myocardial ischemia is a common finding in HCM, reflecting the imbalance between oxygen supply and demand, and it is a major clinical issue in young adolescents with RASopathies (47). Coronary arteries abnormalities have been described in up to 30% of patients affected by RASopathies, and they could contribute to myocardial ischemia (52).

Moreover, cardiac arrhythmias are a major determinant of clinical prognosis in children affected by RASopathies and HCM (42). Supraventricular and ventricular ectopy have been described, and in severe cases, the occurrence of sustained ventricular tachycardia has been reported.

The initial evaluation of a patient affected by HCM should include systematic research for clinical clues or “red flags,” obtained by pedigree analysis, clinical examination, ECG, imaging, and biochemical tests. In particular, the diagnosis of RASopathy may be suggested by facial dysmorphism, lentigines, sensorineural deafness, pulmonary stenosis, or biventricular hypertrophy (3, 53).

Hypertrophic Cardiomyopathy in Noonan Syndrome With Multiple Lentigines

HCM is diagnosed in almost 80% of patients affected by NSML, and it is associated with early-onset presentation and worse clinical outcome, with clinical evidence of LVOTO in up to 40% of the cases (38, 47, 54). Although HCM can be congenital in NSML, it is mostly observed in second infancy, where it precedes the appearance of multiple lentigines. Biventricular hypertrophy can be found in 46% of patients affected by NSML, in association with typical electrocardiographic findings, as a superiorly oriented mean QRS axis, q waves, prolonged QTc, and/or repolarization abnormalities (38). Clinically relevant genotype-phenotype correlations have been described: patients without PTPN11 mutations showed a higher prevalence of family history of sudden death (p = 0.007) and non-sustained ventricular tachycardias (p = 0.05). Of note, mutations of the exon 13 of the PTPN11 gene were associated with severe obstructive HCM (48).

Other cardiac manifestations in NSML include pulmonary valve stenosis, found in almost 23% of the affected individuals, and MV prolapse, clefting, or other morphological abnormalities, which are present in up to 42% of patients. Rarely, NSML has been associated with atroventricular septal defects, LV non-compaction, and coronary arteries abnormalities (21).

Hypertrophic Cardiomyopathy in Costello Syndrome

Approximately 65% of patients affected by CS have HCM, and 40% of them show evidence of CHD (42). Most patients have subaortic septal hypertrophy; however, other patterns such as concentric LV hypertrophy, mild septal thickening, or biventricular involvement have been described (42). In a cohort of 126 patients affected by CS, the mean age at diagnosis was 4.6 years, and no fetal diagnosis of HCM was made. The clinical course was progressive in 38% of the patients and stable in 30% of the patients, and interestingly, almost 11% of the patients showed regression of cardiac hypertrophy.

Although atrial arrhythmias are common among patients with RASopathies, their prevalence seems to be higher in CS, where they can be diagnosed in up to 56% of the patients. Thus, the identification of focal atrial tachycardia could represent a diagnostic clue and, in combination with specific clinical features, should trigger the suspicion of an underlying CS (19, 32, 43). On the other hand, in patients with other RASopathies, multifocal atrial tachycardia (MAT) seems to be associated specifically with RAFI mutations (42).

Hypertrophic Cardiomyopathy in Cardiofaciocutaneous Syndrome

HCM is diagnosed in almost 40% of individuals affected by CFC, although the most common cardiac abnormality is pulmonary valve stenosis, diagnosed in almost 45% of the patients (20). There are lacking data to compare HCM in CS to NS and CFC, although case reports suggest that severe subaortic obstruction requiring surgery is more frequent in CS than in NS and CFC (55).

Hypertrophic Cardiomyopathy in Noonan Syndrome

A lower prevalence of HCM has been described for NS: although more than 80% of the patients show cardiac abnormalities, the prevalence of HCM in NS has been estimated to be 20–23% (17). Prevalence of HCM is slightly higher in a subset of Noonan patients carrying the variant p.Ser2Gly in SHOC2 gene, also known as NS with loose anagen hair (31). NS-associated HCM occurs early in childhood, with a median age at diagnosis of 6 months (56). The distribution of LV hypertrophy is similar to idiopathic variants. Asymmetric septal hypertrophy is the most common pattern, described in 75.6% of Noonan patients. Noteworthy, apical cardiomyopathy is seldom described in NS (57). Electrocardiograms may show several abnormalities, also in the absence of structural abnormalities (56). The magnitude of LV hypertrophy was significantly higher in those with NS or NSML than non-syndromic forms (8.9 as opposed to 6.4...
RAF1 stenosis was more prevalent in carriers of mutation patients, whereas HCM without pulmonary in MV abnormalities (where the prevalence of HCM is up to 65% (10%), atrial septal defect (10%), and rarely tetralogy of Fallot, the coexistence of complex CHD as atrioventricular septal defects (described in almost 65% of the patients), and the left-sided obstructions resulting in MV abnormalities (17, 21). Vascular abnormalities are also described, namely aortic dissection, aortic root dilatation, and aneurysms of the sinuses of Valsalva (17).

Genotype–Phenotype Correlation in RASopathies: The Key to a Target Therapy?

Many clinically relevant genotype–phenotype correlations have been described in RASopathies (Table 2). Among patients with NS, pulmonary stenosis was more common in PTPN11 and SOS1 mutation patients, whereas HCM without pulmonary stenosis was more prevalent in carriers of RAF1 mutations, where the prevalence of HCM is up to 65% (16, 40, 58). It has been suggested that HCM in RASopathies could be caused by increased activation through the RAS-MAPK cascade, causing cardiomyocyte hypertrophy and myocardial fiber disarray (21). Consequently, treatment with Mek1 inhibitors seemed to rescue the cardiac phenotype in mouse Raf1-mutated models (59). Trametinib, a highly selective Mek1/2 inhibitor that seemed to reverse hypertrophic phenotype within 4 months after initiation of treatment, is preceded by a favorable clinical response in a single patient with RIT1-associated HCM (60). On the other hand, specific missense mutations of PTPN11 associated with NSML seem to cause increased activity through the mTOR–PI3K–AKT signaling pathway. Treatment of the PTPN11 (Y279C) mice with rapamycin, an inhibitor of mTOR–PI3K–AKT pathway, normalized HCM (61). Recently, everolimus has been used to prevent acute decompensation of heart failure in severe HCM in patients with NSML, even though no reversal of HCM was observed (62) (Table 3).

Prognosis and Risk of Sudden Cardiac Death

In the subgroup of patients with RASopathies, HCM is a major determinant of the clinical prognosis. In a cohort study, children with NS presented a higher prevalence of congestive heart failure (CHF) (24 vs. 9%) compared with those with idiopathic HCM, and a significant early mortality rate (22% at 1 year) (64). Low cardiac output, significant diastolic dysfunction, and a higher number of interventions have been reported in patients who died for cardiac causes (51, 64).

The stratification of risk for sickle cell disease (SCD) among patients with RASopathies and HCM is not completely understood, and data have been extrapolated from larger studies including pediatric patients affected by sarcomeric HCM (65–67). Recently, an international multicentric observational cohort study including 572 children with HCM has validated age at diagnosis, history of recent unexplained syncope within 6 months before the diagnosis, documented non-sustained VT (defined as ≥3 beats at ≥120 bpm on ambulatory ECG), interventricular septal diameter (IVSD) z score, LV posterior wall diameter (LVPWD) z score, left atrial (LA) diameter z score, and peak resting LVOT gradient on echocardiography as risk factors for SCD in pediatric HCM. Nevertheless, patients with RASopathies were excluded from the analysis (68).

Specific etiologies, as the diagnosis of NSML and, in particular, an arrhythmogenic phenotype as the absence of PTPN11 mutation in NSML, might provide additional risk, but the available evidence is not conclusive to provide a prognostic stratification for SCD in children with RASopathies (48).

Treatment

General management of HCM in RASopathies is based on current clinical practice guidelines. Medical therapy, mainly based on beta-blockers, can be used to relieve symptoms and the degree of obstruction (1). Surgical myectomy is feasible in NS and should be considered in patients who remain symptomatic despite maximal medical therapy (69). Orthotopic heart transplantation is rarely performed, and long-term follow-up studies are needed to assess prognostic implications of heart transplantation in these patients (70). However, it may be considered in those with advanced heart failure, or intractable ventricular arrhythmias, or severe diastolic dysfunction.

GLYCOGEN STORAGE DISEASES

GSDs represent an important cause of HCM in children and are characterized by the formation of glycogen-filled vacuoles in cardiomyocytes (71). Different GSDs are known to be associated with HCM (1, 72, 73); in particular, the most important are represented by Pompe disease (or GSD type IIa), Danon disease (or GSD type IIb), Cori–Forbes disease (or GSD type III), and PRKAG2 syndrome.

Pompe Disease (Glycogen Storage Disease Type IIa)

Introduction

Pompe disease (OMIM code #232300) is a rare and progressive metabolic disorder caused by the partial or complete deficiency of the acid alpha-glucosidase enzyme (GAA). This condition leads to a pathological accumulation of glycogen in several organs, in particular in the nervous system and muscles, including the heart (74).

It is inherited with an autosomal recessive pattern and is the result of homozygotic mutations in GAA (75), which encodes for an enzyme that is responsible for lysosomal glycogen hydrolyzation into glucose. The glycogen accumulation and the lysosomal membrane rupture in the muscle tissue lead to a massive leakage of lytic enzymes responsible for muscle damage (76, 77).
TABLE 3 | Advantages and disadvantages of the available treatments for Pompe disease.

| HCM specific cause        | Specific therapies and future perspective                                                                 |
|---------------------------|-------------------------------------------------------------------------------------------------------------|
| RASopathies               | No specific treatment currently available<br>MEK inhibitors (future perspective)<br>In mouse models of Noonan syndrome, the administration of MEK inhibitors during 4–10 weeks of life could prevent the development of cardiomyopathy. Data from a clinical report showed that MEK inhibitors can induce the regression of cardiac hypertrophy within 4 months of treatment.<br>mTOR inhibitors (future perspective)<br>In mouse models with PTPN11 mutation Y279C, the administration of rapamycin, an inhibitor of mTOR-PI3K-AKT pathway, induced regression of HCM. |
| Pompe disease             | Enzyme replacement therapy<br>Advantages: reduction of cardiac mass and reverse remodeling; long-term efficacy achieved in a subgroup of patients.<br>Disadvantages: high doses required; highly dependent on level of M6PR; does not cross the BBB; possible adverse reactions: ventricular ectopy; transient fall of the left ventricular ejection fraction; immune-mediated reaction.<br>Gene therapy (future perspective)<br>Advantages: improved clearance of glycogen in the muscles; enhanced respiratory and cardiac performance; potential for expressing GAA directly in target tissues.<br>Disadvantages: high vector doses needed; transgene immunogenicity |
| Danon disease             | No specific treatment currently available<br>Gene therapy (future perspective)<br>In mouse models of Danon disease, LAMP2B gene transfer improves metabolic and physiologic function. |
| PRKAG2 syndrome           | No specific treatment currently available<br>Gene therapy (future perspective)<br>In mouse models of PRKAG2 syndrome, GDE gene transfer blocked glycogen accumulation in cardiac and skeletal muscles and improved the muscle functions. |
| Cori–Forbes disease       | No specific treatment currently available<br>Gene therapy (future perspective)<br>In mouse models of Cori–Forbes disease, GDE gene transfer blocked glycogen accumulation in cardiac and skeletal muscles and improved the muscle functions. |
| Mucopolysaccharidoses     | Enzyme replacement therapy<br>Advantages: effective on visceral organs; easy to administer.<br>Disadvantages: has limited impact on poorly vascularized tissues; does not cross the BBB; requires continuous administration; can cause IgG antidrug antibodies formation; can cause infusion-related reactions.<br>Hematopoietic stem cell transplantation<br>Advantages: it is a permanent therapy; increases the long-term survival; can cause the interruption of the disease progression; can cross the BBB.<br>Disadvantages: does not prevent valve dysfunction; can cause GVHD; can cause graft rejection.<br>Gene therapy (future perspective)<br>Advantages: it is a permanent therapy; potentially able to cross the BBB.<br>Disadvantages: can cause off-target gene effects; the long-term effects are unknown.<br>Chaperone therapy (future perspective)<br>Advantages: can cross the BBB; it is not immunogenic.<br>Disadvantages: can cause off-target adverse effects; it is not approved for all the MPSs type. |
| Mitochondrial disorders   | No specific treatment currently available, except for:<br>CoQ<sub>10</sub> deficiency: CoQ<sub>10</sub> supplementation.<br>Thiamine-responsive disorders: thiamine supplementation.<br>In mouse models of Barth syndrome, gene therapy rescued neonatal demise, prevented cardiac dysfunction, and reversed established heart disease.<br>Several treatments are currently on investigations, such as MitoQ antioxidant, MTP-131 peptide (which reduce the ROS release and improving ATP synthesis), inhibitors of mPTP, mitochondrial transplantation, etc. (63) |

BBB, brain–blood barrier; ERT, enzyme replacement therapy; GVHD, graft vs. host disease; M6PR, mannose-6-phosphate receptor; MPSs, mucopolysaccharidoses.

Clinical Presentation and Diagnostic Consideration

Pompe disease is classified in infantile form and late onset, when it presents before and after the 1st year of life, respectively.

The infantile form is generally classified into a classic Pompe disease, which generally presents with a rapidly progressive course with severe cardiomegaly, hepatomegaly, weakness, hypotonia, respiratory distress, infections, and feeding difficulties; and a non-classic Pompe disease, which represents a variant form with slower disease progression and mild or absent cardiomyopathy (78–80). Cardiac involvement of the infantile form of Pompe disease represents the dominant feature of the disease and the major determinant of mortality. Thus, in the infantile form of Pompe disease, chest radiography often shows cardiomegaly, while ECG shows a short PR interval and hypertrophy signs (76). Echocardiography often shows LV hypertrophy with or without LVOTO, mimicking HCM. In particular, cardiac involvement presents in the 1st months of life with severe ventricular hypertrophy (ranging from +2 to +10 or higher z score for LV mass), most notably in the posterior wall and the interventricular septum, which can appear also in intrauterine life. The LV ejection fraction, initially preserved, tend to
fall in the first 5 months moving toward dilated cardiomyopathy with end-stage heart failure in the 1st year of age (81).

The late-onset form includes childhood, juvenile, and adult variants characterized by a slow course and a predominant skeletal muscle involvement (76). Other features of the late-onset form are represented by hypertension, due to loss of aortic compliance, and idiopathic stroke. Preexcitation syndrome, LV hypertrophy, and ascending aorta dilation represent possible cardiac features of late-onset Pompe disease. Respiratory failure is a possible lethal complication caused by the involvement of the respiratory muscle (82).

The diagnosis of Pompe disease is challenging given its heterogeneous presentation. Dry blood spot test is a valid screening method for patients with suspicion of Pompe disease, but the gold standard diagnostic test is the measurement of GAA enzyme activity in skin fibroblasts (74, 76). Indeed, the diagnosis is generally performed demonstrating a significant reduction in GAA enzyme activity and identifying the disease-causing mutations of the GAA gene.

Prognosis and Risk of Sudden Cardiac Death
As stated before, cardiovascular involvement is the major determinant of prognosis in patients with the infantile form of Pompe disease, with the possible evolution to refractory heart failure and death in the 1st year of age (76, 81). On the contrary, in the late-onset form, the prognosis is mainly dependent upon the age of onset with a slower disease progression in those patients manifesting later the disease. In this subgroup, the prognosis is dependent upon the extent of respiratory muscle involvement (82). Sudden cardiac death is extremely rare in patients with Pompe disease.

Treatment
Actually, the standard of care in patients with Pompe disease is represented by enzyme replacement therapy (ERT), based on the discovery of receptor-mediated uptake of lysosomal enzymes related to mannose-6-phosphate receptor (M6PR) (Table 3). The main goal of ERT is to slow down, stabilize, and reverse disease progression. Among the benefits of ERT, there is the reduction of cardiac mass, reverse remodeling, and improvement of cardiac function. The efficacy of this treatment has led to a reduction in the use of inotropes, diuretics, and vasodilators which can exacerbate the LVOTO (76). Recombinant GAA (rhGAA) doses used in patients with Pompe disease are markedly high compared with those used in other lysosomal storage diseases, probably because of the elevated liver absorption (more than 85%), limiting the muscle uptake. Possible side effects are rare and include a transient fall in LV ejection fraction (mostly in the first 12–24 weeks of therapy), ventricular ectopy, and immune-mediated reactions (83). Thus, to improve enzyme bioavailability in tissues, two strategies have been developed: the use of new rhGAA with high affinity for M6PR and the use of pharmacological adjuvants such as beta2agonists (e.g., clenbuterol and albuterol) or chaperones (e.g., glucose analogs duvoglustat and miglustat) (84).

Given the monogenic origin of Pompe disease, it represents an ideal target for gene therapy. In particular, recent progress has been made in the field of gene therapy mediated by adeno-associated virus vectors (AVV), and several preclinical studies demonstrated the efficacy of this treatment based on the improved clearance of glycogen in the muscle and the enhanced respiratory and cardiac performance. However, the limitations are primarily the high vector doses needed and the transgene immunogenicity caused by the increased muscle-specific GAA expression (84–86).

Danon Disease (Glycogen Storage Disease Type IIb)
Introduction
Danon disease (OMIM code #300257) is a rare X-linked disorder with prominent effects on skeletal and cardiac muscle (87), caused by mutations in the LAMP2 (88). The real prevalence of this condition is unclear; however, a disease-causing mutation in LAMP2 has been found in up to 1% of HCM patients (72). LAMP2 is a glycosylated protein that is important in the prevention of the lysosome degradation from its acid hydrolases (89, 90). The impairment of LAMP2 protein function due to gene mutation leads to the accumulation of autophagic material and glycogen (91).

Clinical Presentation and Diagnostic Consideration
Given the X-linked inheritance pattern, the clinical manifestation and the age of presentation are quite different in the two sexes. In males, Danon disease presents at an earlier age and is classically characterized by skeletal myopathy, cardiomyopathy, and intellectual disability.

Danon cardiomyopathy is progressive and usually shows a severe concentric LV hypertrophy (92), which can later progress to LV dilation and heart failure in about 10% of males (93). Conduction abnormalities are also present, manifesting nearly in all of the affected males, and the most common electrocardiographic feature is a short PR interval (preexcitation), present in nearly two thirds of patients (93); the diagnostic flowchart of patients with unexplained left ventricular hypertrophy (LVH) and ventricular preexcitation is shown in Figure 4. Skeletal myopathy manifests in 80–90% of males with progressive proximal muscle weakness (93, 94); it is associated with elevated serum creatine kinase (CK) levels, the presence of intracytoplasmic vacuoles containing autophagic material and glycogen, and the absence of LAMP2 protein expression at skeletal muscle biopsy (93). Other common manifestations in males with Danon disease are represented by learning disability and cognitive defects (in 70–100%) and retinal involvement (in 69%) (95).

On the contrary, females with Danon disease are generally less severely affected. Myocardial involvement is present in 60–100% of females, with an equal prevalence of HCM and dilated cardiomyopathy (93); in addition, conduction abnormalities are present in almost all patients (93, 94). Muscle weakness is generally mild to asymptomatic in females, with mild elevation or
normal serum CK levels (96). Likewise, learning disabilities and cognitive defects are less frequent.

In patients with clinically suspect of Danon disease or unexplained LV hypertrophy, the diagnosis is supported by the presence of normal acid maltase levels on muscle biopsy, the deficiency of LAMP2 protein by immunohistochemistry, the evidence of autophagic vacuole accumulation by microscopy, and the presence of a disease-causing mutation of LAMP2 (97). Therefore, genetic testing, due to its non-invasive nature and the inclusion of LAMP2 in HCM genetic testing panels, actually represents the most common tool for identifying Danon disease.

**Prognosis and Risk of Sudden Cardiac Death**

Heart failure and arrhythmia constitute the leading cause of morbidity and mortality in patients with Danon disease. Recently, data from a multicenter European registry have shown that Danon disease runs a malignant course in both genders, due to cardiac complications (98). In particular, among the 57 patients evaluated (30 males and 27 females), 53% had a heart failure hospitalization, 27% underwent heart transplantation or received an LV assist device, and 30% of patients died during follow-up. Moreover, in this cohort, SCD occurred in three female patients, and appropriate implantable cardioverter-defibrillator (ICD) interventions for ventricular tachycardia/fibrillation were evidenced in six patients, underlying the high risk of SCD in this population (98).

Similar to sarcomeric HCM, SCD in Danon disease is associated with the presence of specific risk factors, including symptomatic arrhythmias, severe hypertrophy, reduced ejection fraction, extended fibrosis on cardiac magnetic resonance (CMR), and family history of SCD (99). However, the association between these risk factors and SCD is based on few studies and with small sample size cohort; thus, the indication for ICD implantation must be individualized on a case-by-case basis.

**Treatment**

There is no etiological treatment for Danon disease (Table 3), and the management should be based on a multidisciplinary team-based approach (95). The management of HCM should follow the current guidelines (1, 9), considering that in patients with Danon disease it may present earlier and may progress more rapidly compared with sarcomeric forms of HCM, in particular in males. Therefore, management with inotropic negative or chronotropic negative agents should be used with caution in Danon disease, considering the possible development of systolic LV dysfunction and/or atrioventricular block (92), which represents possible complications of the disorder.

Recently, Manso et al. (100) tested the efficacy of AAV-9-mediated gene therapy delivering the human LAMP2B gene in a mouse model of Danon disease and showed that gene therapy restored protein expression in multiple organs.
improved metabolic abnormalities and cardiac function, and increased survival.

Cori–Forbes Disease (Glycogen Storage Disease Type III)
Introduction
Among glycogen storage diseases, GSD type III (OMIM code #232400), also called Cori–Forbes disease, is one of the rare disorders of glycogenolysis associated with the development of LV hypertrophy (101). The incidence of GSD type III is ~1:100,000 in the United States (101). GSD type III is an autosomal recessive disorder caused by AGL mutations (102), causing non-functional glycogen debranching leading to the storage of limited dextrin.

Clinical Presentation and Diagnostic Consideration
Two principal forms have been described: GSD type IIIa, characterized by involvement of the liver and the cardiac and skeletal muscle, and GSD type IIIb, by only liver involvement (102, 103). In infants and in children, the principal features are represented by hepatomegaly, hypoglycemia, failure to thrive, recurrent illness, and/or infection (104). Cardiac involvement is common in GSD type IIIa, mostly starting in the first decade of life (104). The International Study on Glycogen Storage Disease (ISGSDIII) (104) showed that cardiac involvement was present in 58% of patients and that nearly two thirds of these patients had electrophysiographic and/or echocardiography signs of LV hypertrophy, whereas the other one third showed a different form of cardiac hypertrophy (i.e., septal, right ventricular, or biventricular hypertrophy). The presence of severe cardiomyopathy is reported in 15% of patients and represents almost the important cause of death in these patients (104, 105). The diagnosis requires liver and/or muscle biopsy or can be formulated through the identification of a disease-causing homozygotic mutation in AGL (106).

Treatment
Unfortunately, a specific treatment for GSD III is not currently available, and current treatments are based on symptomatic and dietary management to control blood glucose levels (104, 106, 107). However, due to its monogenic nature, it is a suitable candidate for AAV-mediated gene therapy. Recently, Lim et al. (108) showed that in mouse models of GSD III, the AAV-mediated gene therapy blocked the glycogen accumulation in both cardiac and skeletal muscle and improved the muscle functions.

PRKAG2 Syndrome
Introduction
PRKAG2 syndrome is a metabolic disorder, inherited with an autosomal dominant pattern, which is characterized by LV hypertrophy, conduction abnormalities, and ventricular preexcitation, caused by mutations in PRKAG2 (71, 109). PRKAG2 mutation is reported in nearly 1% of patients with HCM (72) and in 29% of those with both LV hypertrophy and preexcitation on ECG (110, 111). PRKAG2 encodes for the γ2 regulatory subunit of AMP-activated protein kinase (AMPK) (112). PRKAG2 mutation leads to structural changes of AMPK (113–115), leading to impaired myocyte glucidic uptake, which results in intracellular glycogen and amylopectin deposition, finally causing storage cardiomyopathy (116). PRKAG2 mutations have also been linked to conduction abnormalities and ventricular preexcitation; however, the underlying mechanism of this association is still unclear (117).

Clinical Presentation and Diagnostic Consideration
PRKAG2 syndrome may present different severity degree of both the ventricular hypertrophy and arrhythmic manifestations (118). The onset of symptoms commonly occurs within the first three decades of life and arrhythmic symptoms (i.e., palpitations, lipotomies, and syncopal episodes) represent the most common disease presentation (72).

The most common electrocardiographic feature of PRKAG2 syndrome is a short PR interval, found in nearly two thirds of patients (72) (Figure 4); other electrocardiographic abnormalities are represented by the right bundle branch block, different patterns of intraventricular conduction abnormalities, and sinoatrial blocks (119). LVH, evidenced thought echocardiography or CMR, often showed an eccentric distribution with a progressive wall thickness increase in the large part of affected individuals (72). CMR is important in early detecting myocardial involvement. In the early phase of the disease, a focal mid-infero-lateral pattern may be present, and T1 values may be reduced, while a diffuse myocardial involvement is generally evidenced in patients with an advanced phase of the disease, and the presence of fibrosis causes T1 value elevation (109).

In the advanced phase, evolution forward LV dilation and dysfunction are possible, with the subsequent development of heart failure (120). Supraventricular tachyarrhythmias were evidenced in more than one third of PRKAG2 syndrome patients, and the large part of these showed an accessory pathway on the electrophysiological study (119, 121, 122). They are mainly represented by atrial fibrillation and flutter; and their complications are represented by stroke and ventricular arrhythmias, sometimes leading to SCD (72, 119, 122). Conduction system dysfunctions, such as advanced atrioventricular blocks, marked sinus bradycardia, and sinus blocks are present in about half of PKAG2 syndrome patients, leading, in a large part of them, to pacemaker implantation (1, 112). The family screening and, when indicated, genetic testing are of great importance for diagnosis.

Prognosis and Risk of Sudden Cardiac Death
Heart failure development and arrhythmia, and both bradyarrhythmia and tachyarrhythmia, constitute the leading cause of morbidity and mortality in patients with PRKAG2 syndrome. SCD occurs in about 10% of PRKAG2 syndrome patients, mainly as a consequence of advanced atrioventricular block or supraventricular tachycardia degenerated in ventricular
fibrillation, or from massive hypertrophy (72, 123, 124). However, current data are not sufficient to clearly define the precise pathophysiologic process leading to SCD.

**Treatment**

Given the numerous life-threatening consequences of PRKAG2 syndrome, early identification and management of its complications is mandatory. Actually, no specific guidelines have been formulated for PRKAG2 syndrome. The management of HCM should follow the current guidelines (1, 9). Pacemaker implantation is recommended in patients with symptomatic sinus node dysfunction or atrioventricular block. ICD implantation in primary prevention should be performed after a careful evaluation of the individual risk factors, such as familial history of SCD, arrhythmic syncopal episodes, severe LV hypertrophy, non-sustained ventricular tachycardia, and extended fibrosis on CMR (4, 119).

**LYSOSOMAL STORAGE DISEASES**

Lysosomal storage diseases are a heterogeneous group of inherited disorders characterized by the accumulation of undigested or partially digested macromolecules, leading to cellular dysfunction and organomegaly. The forms that most commonly cause HCM are represented by mucopolysaccharidoses (MPSs).

**Mucopolysaccharidoses**

**Introduction**

The MPSs (OMIM code #252700) are a heterogeneous group of lysosomal storage disorders caused by the functional deficiency of one of the lysosomal enzymes involved in the catabolism of glycosaminoglycans (GAGs) (125). Individuals with MPSs are affected by progressive deposition of incompletely degraded GAGs within potentially all organ systems, although the specific distribution depends on the specific disease. Except for MPS type II, which is inherited with an X-linked recessive pattern, all the MPSs are inherited with autosomal recessive pattern (126).

**Clinical Presentation and Diagnostic Consideration**

Typical manifestations include skeletal and joint deformities, growth and intellectual disability, central nervous system involvement, respiratory difficulty, gastrointestinal disorders, cardiovascular diseases, and ocular and hearing alterations (127). Cardiovascular involvement is generally present, and it occurs earlier and more frequently in MPS type I, type II, and type VI. Cardiac involvement in MPSs is caused by the massive accumulation of dermatan sulfate especially into valves and great vessels, where this GAG is normally present in a large amount. Its deposition leads to the infiltration of granular cells into valves, myocardial walls, coronary arteries, and conduction system inducing inflammation mediated by Toll-like 4 receptor pathway (128). The principal expression of cardiac involvement is represented by valvular regurgitations and stenosis, mainly involving the left-sided valves, caused by thickening of leaflets or papillary muscles and shortening of subvalvular apparatus. The presence of HCM, endocardial thickening, dilated cardiomyopathy with reduced ejection fraction, and pulmonary hypertension has also been described (129, 130). Typically, LV hypertrophy and diastolic dysfunction occur in the early phases, while LV dilation and systolic dysfunction are common in the final disease stage. Moreover, coronary artery disease and systemic hypertension are common in patients with MPSs and have been associated with the diffuse intimal proliferation from GAG deposition, while electrophysiologic anomalies such as atrioventricular blocks are related to fibrosis of the conduction system (128, 131, 132).

The enzyme activity assays on fibroblasts, leucocytes, or serum are the gold standard for a definitive diagnosis. Gene analysis can identify the mutations present; in particular, homozygous mutation in the gene encoding alpha-L-iduronidase (IDUA) is diagnostic for MPS type I, in the gene encoding iduronate-2-sulfatase (IDS) for MPS type II, and in the gene encoding arylsulfatase B (ARSB) for MPS type VI (125).

**Prognosis and Risk of Sudden Cardiac Death**

Regardless of phenotype, all forms of MPS are associated with increased morbidity and mortality. However, the prognosis of patients with MPS mainly varies according to the type of MPS and the residual level of the deficient enzyme. For example, in MPS I H, the most severe phenotype, patients often die in the first decade of life for infectious, respiratory, or cardiac complications. Cardiovascular cause of death is mainly caused by advanced heart failure, while SCD or death from coronary occlusion is rare (133, 134).

**Treatment**

In MPS patients, cardiac surgery for valve disease is often performed with success, and standard pharmacological therapy for heart failure management is commonly used in current clinical practice (128). Actually, ERT and hematopoietic stem cell transplantation (HSCT) represent the standard of care for most MPS diseases (Table 3). ERT, approved for MPSs I, II, IV, VI, and VII, has improved pulmonary function, walking ability, muscular pain, and organomegaly. This treatment has shown a significant increase in systolic and diastolic functions and an important hypertrophy regression. However, ERT and HSCT are ineffective on poorly vascularized sites such as cardiac valves, corneas, and cartilage (128). The most common adverse events with ERT are IgG antidrug antibody formation and infusion-related hypersensitivity reactions (135–137). HSCT is used in all forms of MPS except MPS III, even if several studies show important benefits of this treatment only in MPS I. Its major adverse effects are graft vs. host disease (GVHD) and graft rejection. Beneficial effects are the significant increase of long-term survival, interruption of pulmonary and cardiac disease progression, especially regarding coronary artery occlusion and ventricular hypertrophy, and the attenuation of some neurocognitive symptoms thanks to its ability to cross the brain–blood barrier (BBB) (138). In contrast to ERT, HSCT is considered a permanent treatment. Recently, the association
between ERT and HSCT seems to decrease the likelihood of GVHD and improve therapeutic efficacy (139–141). Among new approaches actually undergoing testing, there is gene therapy. This treatment, based on the direct infusion of viral vectors expressing the functional gene (in vivo gene therapy) or on the infusion of modified and transduced cells form recipient patient (ex vivo therapy), has the advantage to promote continuous enzyme secretion and to be a permanent therapy (142). Pharmacological chaperone therapy aims to provide the correct folding and the highest stability possible of the mutant proteins, avoiding their deposition and aggregation. These little molecules cross BBB and are not immunogenic, but they can present off-target adverse effects and are not currently approved for MPS disorders (143).

MITOCHONDRIAL DISORDERS

Introduction
Mitochondrial disorders represent an extremely heterogeneous group of disorders caused by the dysfunction of the mitochondrial respiratory chain. Several proteins are responsible for the integrity of the mitochondrial structure and function, with the major part encoded by the nuclear DNA (nDNA) and the minor part by the mitochondrial DNA (mtDNA) (144).

For this reason, mitochondrial disorders are a challenging area of genetics (144, 145); indeed, this condition results in different possible inheritance patterns of mitochondrial disorder (i.e., autosomal dominant, autosomal recessive, X-linked, and maternal). Mutations in mtDNA or nDNA genes result in mitochondrial dysfunction, thus resulting in mitochondrial disorders (146). Mitochondrial disorders are typically multiorgan disorders, especially involving those organs with high-energy requirement (147), and it can clinically manifest in the neonatal phase, childhood, or adulthood (148).

Because cardiac muscle is one of the high-energy-demanding tissues, the myocardial involvement (i.e., mitochondrial cardiomyopathy) occurs in about 20–40% of children with mitochondrial disease (147), and it can present as an isolated feature or part of a multiorgan involvement (149). HCM is the most common form of mitochondrial cardiomyopathy; however, other forms of cardiomyopathies are possible.

Clinical Presentation and Diagnostic Consideration
Several mitochondrial syndromes showed a myocardial involvement as a part of their multiorgan spectrum (149). In these conditions, typically associated with mtDNA mutations, myocardial involvement is characterized by cardiomyopathy and/or conduction abnormalities. In particular, myocardial involvement may be associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS syndrome) (150); myoclonic epilepsy with ragged red fibers (MERRF syndrome) (151); and neurogenic muscle weakness with sensory neuropathy, ataxia, and pigmentary retinopathy (NARP syndrome) (152). Clinical presentation is extremely variable, with the early onset generally associated with worse outcome and the later onset with mild clinical presentation (63).

Next to the classical mitochondrial syndrome, several other mitochondrial disorders associated with HCM have been identified and can be classified in mitochondrial disorders caused by single or multiple respiratory chain complex deficiencies (153), CoQ10 deficiency (154), mitochondrial transporters deficiency, disorders characterized by 3-methylglutaconic aciduria (e.g., Barth syndrome), disorders of mitochondrial iron metabolism (e.g., Friedreich ataxia), and disorders of mitochondrial β-oxidation and carnitine metabolism (149) (Figure 5).

Deficiency of individual or multiple respiratory chain might result from a mutation in mtDNA or nDNA mitochondrial-related genes, and in both these conditions, it is possible that cardiomyopathy manifests as an isolated feature or in the spectrum of a multisystem disorder (153).

A comprehensive diagnostic workup is required to obtain a final diagnosis (Figure 5). The inheritance pattern, the pattern of organ involvement, the presence of specific findings on clinical and instrumental evaluation, and typical biochemical abnormalities might narrow the differential diagnosis.

Specific Forms: Barth Syndrome
Barth syndrome (OMIM code #302060) is a rare X-linked genetic disease due to mutation in TAZ gene, which encodes for tafazzin, a phospholipid transacylase that plays an important role in the remodeling of cardioliop. Cardiomyopathy is present in nearly 70% of Barth syndrome patients and appears in the 1st year of age, usually manifesting as dilated cardiomyopathy or LV non-compaction; HCM appears to be rarer (155, 156). Other clinical manifestations include skeletal myopathy, growth delay, neutropenia, and increased urinary excretion of 3-methylglutaconic acid (3-MGCA) (157).

Specific Forms: Friedreich Ataxia
Friedreich ataxia (OMIM code #22930) is a neurodegenerative disorder, inherited with an autosomal recessive pattern, caused by the homozygous GAA triplet repeat expansion in the FXN, which encodes for the protein frataxin. The first symptoms usually appear in the second decades of life, and the clinical presentation includes progressive ataxia, dysarthria, peripheral neuropathy, and diabetes mellitus (158). Cardiovascular involvement, usually manifesting as unexplained LVH appearance during adolescence and is present in nearly two thirds of patients; however, in some cases, the disease can progress to progressive LV dilatation and dysfunction, which can result in heart failure and cardiovascular death.

Treatment
To date, the only mitochondrial disorders with an etiologic treatment are those caused by CoQ10 deficiency and thiamine-responsive disorders (159) (Table 3). However, target therapies are present for specific mitochondrial diseases. For monogenic disorder, one attractive strategy is AAV gene replacement therapy. For example, in mouse models of Barth syndrome, the AAV-mediated gene therapy rescued neonatal demise, prevented cardiac dysfunction, and reversed established heart disease (160),
FIGURE 5 | Proposed algorithm for the diagnosis of mitochondrial cardiomyopathies. CACT, carnitine-acylcarnitine translocase; CPTII, carnitine palmitoyltransferase II; FFA, free fatty acids; LCHAD/MTP, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; LHON, Leber’s hereditary optic neuropathy; MADD, multiple-acyl-CoA dehydrogenase deficiencies; MELAS, mitochondrial encephalopathy, lactic acidosis, stroke-like episodes; MERFF, myoclonic epilepsy with ragged red fibers; MGA, methylglutaconic aciduria; NARP, neurogenic muscle weakness with sensory neuropathy; VLCADD, very-long-chain acyl-CoA dehydrogenase deficiency.

Unexplained left ventricular hypertrophy
and 1 clinical “red flag” for mitochondrial disease

1. Refer to third level cardiomyopathy centre for diagnosis confirmation
2. Consider checking: urine and plasma organic acids, plasma lactates, acylcarnitine and FFAs

Molecular genetic testing for target genes

If negative for target genes mutations, consider further investigation:

Tissue sampling from skeletal muscle

1. Histology: testing for cellular morphology, mitochondrial accumulation, citochrome c deficient cells

2. Biochemistry: Measurement of respiratory chain complex I-V enzyme activities, to identify pattern of deficiency and direct further investigations

Molecular genetics

Pyrosequencing: to detect mtDNA point mutations
Southern blot: to detect mtDNA rearrangements
mtDNA sequencing
Nuclear DNA analysis
suggesting that gene therapy might be a therapeutic option for patients with Barth syndrome.

In patients with mitochondrial disorders, heart transplantation may be considered in patients with severe isolated cardiomyopathy or when the eventually extracardiac manifestations are mild and appear non-progressive (161).

**CONCLUSIONS**

HCM in children represents a large heterogeneous group of disorders. A comprehensive approach, including medical group, physical examination, detailed cardiac imaging, and attention to possible extra-cardiac abnormalities, is required to suspect a specific disorder and to perform a specific diagnosis. The early referral to third-level cardiomyopathy center may be useful in order to start tailor management and potentially initiate targeted genotype-based therapies for these rare conditions.

**AUTHOR CONTRIBUTIONS**

EM, MR, and GL contributed to the conception and design of the work. EM, MR, ML, FDF, RP, FV, and GL drafted the manuscript. All the authors critically revised the manuscript. All the authors gave final approval and agreed to be accountable for all aspects of work ensuring integrity and accuracy. All the authors have read and agreed to the published version of the manuscript.

**REFERENCES**

1. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggreve M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. (2014). 35:2733–79. doi: 10.1093/eurheartj/ehu284
2. Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry. Circulation. (2007) 115:773–81. doi: 10.1161/CIRCULATIONAHA.106.621185
3. Limongelli G, Monda E, Brayman S, Gragnano F, Rago M, Natale F, et al. Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. Int J Cardiol. (2020) 299:86–91. doi: 10.1016/j.ijcard.2019.06.073
4. Esposito A, Monda E, Gragnano F, Cesaro A, Natale F, et al. Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C677T7 polymorphism. Eur J Prev Cardiol. (2019) 12:2047487319888596. doi: 10.1177/2047487319888596
5. Monda E, Sarubbi B, Russo MG, Caiazza M, Magrelli C, Magrelli J, et al. Unexplained sudden cardiac arrest in children: clinical and genetic characteristics of survivors. Eur J Prev Cardiol. (2020) 26:2047487320940863. doi: 10.1177/2047487320940863
6. Limongelli G, Nunziato M, D’Argenio V, Esposito MV, Monda E, Massaccara C, et al. Yield and clinical significance of genetic screening in elite and amateur athletes. Eur J Prev Cardiol. (2020) 2:2047487320934265. doi: 10.1177/2047487320934265
7. Barretta F, Mirra B, Monda E, Caiazza M, Lombardo B, Tinto N, et al. The hidden fragility in the heart of the athletes: a review of genetic biomarkers. Int J Mol Sci. (2020) 21:E6682. doi: 10.3390/ijms21186682
8. Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spencer KL, et al. Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Card Fail. (2012) 18:396–403. doi: 10.1016/j.cardfail.2012.01.017
9. Writing Committee Members, Ommen SR, Mital S, Burke MA, Day SM, Deswal A, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. (2020). 142:e558–631. doi: 10.1161/CIRCULATIONAHA.116.037168
10. Lipshultz SE, Law YM, Asante-Korang A, Austin ED, Dipchand AI, Everitt MD, et al. Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American heart association. Circulation. (2019) 140:e9–68. doi: 10.1161/CIRCULATIONAHA.119.036062
11. Rapezzi C, Barbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Heliö T, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC working group on myocardial and pericardial diseases. Eur Heart J. (2013) 34:1448–58. doi: 10.1093/eurheartj/ehs397
12. Maurizi N, Passantino S, Spaziani G, Girolami F, Arretti A, Targetti M, et al. Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events. JAMA Cardiol. (2018) 3:520–5. doi: 10.1001/jamacardio.2018.0789
13. Monda E, Limongelli G. The hospitalizations in hypertrophic cardiomyopathy: “The dark side of the moon”. Int J Cardiol. (2020) 318:101–2. doi: 10.1016/j.ijcard.2020.08.054
14. Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, et al. Pediatric Cardiomyopathies. Circ Res. (2017) 121:855–73. doi: 10.1161/CIRCRESAHA.116.309386
15. Monda E, Palmiero G, Rubino M, Verrillo F, Amadio F, Di Fraia F, et al. Molecular basis of inflammation in the pathogenesis of cardiomyopathies. Int J Mol Sci. (2020) 21:E6462. doi: 10.3390/ijms21186462
16. Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAK pathway: phenotypic spectrum and molecular mechanisms. Am J Med Genet. (2010) 1214:99–121. doi: 10.1002/ajmg.b.30970.x
17. Roberts AE, Allanson JE, Tartagl M, Gelb BD. Noonan syndrome. Lancet. (2013) 381:333–42. doi: 10.1016/S0140-6736(12)61023-X
18. Tartaglia M, Gelb BD, Zunker K. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. (2011) 25:161–79. doi: 10.1016/j.beem.2010.09.002
19. Hennekam RC. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet. (2003) 117C:42–8. doi: 10.1016/j.ajmgc.2003.01.001
20. Pierpont ME, Magoulas PL, Adi S, Kavamura MI, Neri G, Noonan J, et al. Cardiac-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. (2014) 134:e1149–62. doi: 10.1542/peds.2013-3189
21. Calcagni G, Adorizio R, Martellini S, Grueter G, Baban A, Versacci P, et al. Clinical presentation and natural history of hypertrophic cardiomyopathy in rasopathies. Heart Fail Clin. (2018) 14:225–35. doi: 10.1016/j.hfcl.2017.12.005
22. Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B. Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr. (2011) 135:703–6. doi: 10.1016/j.jpeds.2010.09.083
23. Noonan JA, Raaijmakers R, Hall BD. Adult height in Noonan syndrome. Am J Med Genet A. (2003) 123A:68–71. doi: 10.1002/ajmg.a.20502
24. Marcus KA, Sweep FG, van der Burgt I, Noordam C. Impaired sertoli cell development in Noonan syndrome: a longitudinal study. Arch Dis Child. (2008) 93:1079–84. doi: 10.1136/adc.2007.134638
25. Dallapiccola B, Toscano A, Digilio MC. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. (2014) 134:e1149–62. doi: 10.1542/peds.2013-3189
26. Noordam C, van der Burgt I, Nickel R, Versacci P, et al. Clinical presentation and natural history of hypertrophic cardiomyopathy in rasopathies. Heart Fail Clin. (2018) 14:225–35. doi: 10.1016/j.hfcl.2017.12.005
39. Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, et al. Germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Am J Hum Genet. (2008) 83:708–11. doi: 10.1086/529954
40. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martini S, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes. J Am Coll Cardiol. (2008) 51:1093–100. doi: 10.1016/j.jacc.2008.02.028
41. Limongelli G, Pacileo G, Limongelli G, Gagliardi MG, Santoro G, Digilio MC, et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. J Med Genet. (2007) 44:1022–6. doi: 10.1136/jmg.2007.050450
42. Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, et al. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol. (2007) 100:736–79. doi: 10.1016/j.jacc.2007.03.019
43. Caiazza M, Rubino M, Monda E, Passariello A, Fusco A, Cirillo A, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet. (2010) 87:250–7. doi: 10.1016/j.ajhg.2010.06.015
44. Ratnasingham DL, Chong LW, Zelikoff JT, Kurokawa S, Schoenfelder S, et al. Activation of the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. (2007) 44:763–71. doi: 10.1136/jmg.2007.050450
45. Yoon G, Rosenberg J, Blaser S, Rauen KA. Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol. (2007) 49:894–9. doi: 10.1111/j.1469-8749.2007.08894.x
46. Rodriguez-Viciana P, Rauen KA. Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Mol Cancer Res. (2008) 6:277–89. doi: 10.1158/1535-7163.MCR-07-0381
47. Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P, et al. Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol. (2007) 100:736–79. doi: 10.1016/j.jacc.2007.03.019
48. Limongelli G, Sarkozy A, Pacileo G, Calabrò P, Digilio MC, Maddaloni V, et al. Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. J Am Coll Cardiol. (2008) 51:1093–100. doi: 10.1016/j.jacc.2008.02.028
49. Cerrato F, Pacileo G, Limongelli G, Gagliardi MG, Santoro G, Digilio MC, et al. A severe Noonan syndrome phenotype. Cardiol Young. (2008) 18:575–80. doi: 10.1016/j.cjcard.2007.08.068
50. Maron MS, Olivetto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. (2011) 124:40–7. doi: 10.1161/CIRCULATIONAHA.110.985812
51. Calcagni G, Limongelli G, D’Ambrosio A, Gesualdo F, Digilio MC, Baban A, et al. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. Int J Cardiol. (2017) 245:92–8. doi: 10.1016/j.ijcard.2017.07.068
52. Calcagni G, Gagliostro G, Limongelli G, Unolt M, De Luca E, Digilio MC, et al. Atypical cardiac defects in patients with RASopathies: updated data on CARNET study. Birth Defects Res. (2020) 112:31–31. doi: 10.1002/bdr2.1670
53. CaisaZZa M, Rubino M, Monda E, Passariello A, Fusco A, Cirillo A, et al. Combined PTPN11 and MYBP3 genes mutations in an adult patient with Noonan syndrome and hypertrophic cardiomyopathy. Genes. (2020) 11:E947. doi: 10.3390 Genes11080947
54. Lauriol J, Kontaridis MI. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc Med. (2011) 21:97–104. doi: 10.1016/j.tcm.2012.03.006
55. Güvenç O, Sengül FS, Saygi M, Ergül Y, Güzeltaş A. Hipertrofik kardiyomiyopati ve Costello sendromu: Olgu sunumu eşliğinde literatürün gözlen çiğilmesi [Hypertrophic cardiomyopathy and Costello syndrome: review of recent related literature with case report]. Turk Kardiyol Dernek Ars. (2014) 42:767–70. doi: 10.5555/tkda.2014.55556
56. Sanchez-Cascos A, The Noonan syndrome. Eur Heart J. (1983) 4:223–9. doi: 10.1093/oxfordjournals.eurheartj.a061452
57. Nishikawa T, Ishiyama S, Shimojo T, Takeda K, Kasajima T, Momma K. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome associated with the Raf1(L613V) mutation. Hum Mutat. (2007) 29:188–93. doi: 10.1002/humu.20955
58. Sanchez-Cascos A. The Noonan syndrome. Eur Heart J. (1983) 4:223–9. doi: 10.1093/oxfordjournals.eurheartj.a061452
59. Hahn A, Lauriol J, Kontaridis MI. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc Med. (2011) 21:97–104. doi: 10.1016/j.tcm.2012.03.006
60. Suzuki K, Takeda K, Sakamoto H, Momma K. Hypertrophic cardiomyopathy in Noonan syndrome. Acta Paediatr Jpn. (1996) 38:379–83. doi: 10.2169/apjps.38.379
61. Marin TM, Keith K, Conner DA, Guha P, Kalaitzidis D, et al. Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-Inhibition. J Pediatr. (2012) 161:531–6. doi: 10.1016/j.jpeds.2012.08.061
62. Wiegand G, et al. Hypertrophic cardiomyopathy in Noonan syndrome. Acta Paediatr Jpn. (2008) 50:398–402. doi: 10.2169/apjps.50.398
63. Minamitake K, Nakamura T, Momma K. Hypertrophic cardiomyopathy in a patient with Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest. (2012) 121:1026–43. doi: 10.1172/JCI44972
64. Hahn A, Lauriol J, Thul I, Behnke-Hall K, Logeswaran T, Schänzer A, et al. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome.
syndrome with multiple lentigines: palliative treatment with a rapanycin analog. *Am J Med Genet A.* (2015) 167A:744–51. doi: 10.1002/ajmg.a.39682
63. Brambilla A, Fabbri S, Olivotti I, Calabri GB, Porcedda G, De Simone L, et al. Clinical profile and outcome of cardiac involvement in MELAS syndrome. *Int J Cardiol.* (2019) 276:14–9. doi: 10.1016/j.ijcard.2018.09.1051
64. Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. *Am Heart J.* (2012) 164:442–8. doi: 10.1016/j.ahj.2012.04.018
65. Limongelli G, Pacileo G, Calabrò R. Is sudden cardiac death predictable in LEOPAD syndrome? *Cardiol Young.* (2006) 16:599–601. doi: 10.1016/S1047-9511(06)001247
66. Maron BJ, Tajik AJ, Ruttenberg HD, Graham TP, Atwood GF, Victorica BE, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. *Circulation.* (1982) 65:57–17. doi: 10.1161/01.CIR.65.1.7
67. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy–a risk factor for sudden death. *N Engl J Med.* (1998) 339:1201–9. doi: 10.1056/NEJM199810223391803
68. Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. *Circulation.* (2020) 142:217–29. doi: 10.1161/CIRCULATIONAHA.120.047235
69. Poterucha JT, Johnson JN, O'Leary PW, Connolly HM, Niaz T, D'Andrea JT, et al. Treatment of lysosomal storage disorders : progress with enzyme replacement therapy. *Drugs.* (2007) 67:297–716. doi: 10.2165/00003495-200767180-00005
70. Sun B, Zhang H, Franco LM, Young SP, Schneider A, Bird A, et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. *Mol Ther.* (2005) 11:57–65. doi: 10.1016/j.ymthe.2004.10.004
71. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease mimicking hypertrophic cardiomyopathy. *Circulation.* (2002) 105:829–34. doi: 10.1161/01.CIR.105.12.829
72. Bay LB, Denzler I, Durand C, Erioa H, Frabasill J, Fainboum A, et al. Infantile-onset Pompe disease: diagnosis and management. *Arch Pediatr.* (2011) 17:271–8. doi: 10.1016/j.arcped.2010.02.024
73. Engel AG, Gomez MR, Seybold ME, Lambert EH. The spectrum and diagnosis of acid maltase deficiency. *Neurology.* (1973) 23:95–106. doi: 10.1212/WNL.23.1.95
74. Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. *Genet Med.* (2012) 14:135–42. doi: 10.1038/gim.2011.4
75. Ronzitti G, Collaud F, Laforet P, Mingozzi F. Progress and challenges of gene therapy for Pompe disease. *Annu Transl Med.* (2019) 7:287. doi: 10.21037/atm.2019.04.67
76. Kishnani PS, Steiner RD, Bali D, Byrne BJ, Case LE, et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: a multicenter European registry. *Circ Cardiovasc Genet.* (2012) 6:215–21. doi: 10.1161/CIRCGEN.120.003117
77. Manso AM, Hashem SI, Nelson BC, Gault E, Soto-Hermida A, Villarruel E, et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multigorgan dysfunction in a murine model of Danon disease. *Sci Transl Med.* (2020) 12:eaaat1744. doi: 10.1126/scitransmed.aaa1744
101. Vertilus SM, Austin SL, Foster KS, Boyette KE, Bali DS, Li JS, et al. Echocardiographic manifestations of glycogen storage disease III: increase in wall thickness and left ventricular mass over time. *Genet Med. (2010) 12:413–23. doi: 10.1097/GIM.0b013e3181e9e797*

102. Yang-Feng TL, Zheng K, Yu J, Yang BZ, Chen TY, Kao FT. Assignment of the human glycogen debrancher gene to chromosome 1p21. *Genomics. (1992) 13:931–4. doi: 10.1006/geno.1992.1003-B*

103. Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. *J Clin Invest. (1996) 98:352–7. doi: 10.1172/JCI118799*

104. Sentner CP, Hoogeveen JI, Weinstein DA, Santer R, Murphy E, McKiernan PJ, et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. *J Inherit Metab Dis. (2016) 39:697–704. doi: 10.1007/s10545-016-9932-2*

105. Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, et al. Glycogen storage disease type III: clinical profile of patients with glycogen storage disease type III: a clinical description of seven cases. *J Inherit Metab Dis. (2015) 38:573–80. doi: 10.1007/s10545-014-9787-1*

106. Lin HY, Chuang CK, Lee CL, Chen MR, Sung KT, Lin H, et al. Familial pseudo-Wolff-Parkinson-White syndrome. *J Pediatr Neurol. (2009) 2:485–91. doi: 10.1161/jpedsneurol.109.003121*

107. Michon CC, Gargiulo M, Hahn-Barma V, Petit F, Nadaj-Pakleza A, Herson VY. Amp-activated protein kinase regulation and familial Wolff-Parkinson-White syndrome. *J Cardiovasc Electrophysiol. (1999) 10:629–35. doi: 10.1111/j.1540-8167.1999.tb00339.x*

108. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, et al. Familial pseudo-Wolff-Parkinson-White syndrome. *J Cardiovasc Electrophysiol. (2006) 17:724–32. doi: 10.1111/j.1540-8167.2006.00485.x*

109. Muenzer J. Overview of the mucopolysaccharidoses. *Rheumatol. (2011) 50(Suppl. 5):v4–12. doi: 10.1093/rheumatology/ker394*

110. Lin HY, Lin SP, Chuang CK, Chen MR, Chen BF, Wraith JE. Identification of a gene responsible for mucopolysaccharidosis II (Hunter syndrome). *Eur J Pediatr. (2005) 164:825–30. doi: 10.1007/s00431-005-0872-6*

111. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, et al. Electrophysiologic characteristics of accessory atrioventricular connections in an inherited form of Wolff-Parkinson-White syndrome. *Heart Rhythm. (2011) 8:55–64. doi: 10.1016/j.hrthm.2010.09.081*

112. Poyhonen P, Hiippala A, Ollila L, Kaasalainen T, Hänninen H, Helio T, et al. Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations. *J Cardiovasc Magn Reson. (2015) 17:89. doi: 10.1186/s12968-015-0192-3*

113. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. *N Engl J Med. (2005) 352:362–72. doi: 10.1056/NEJMoa033349*

114. MacRae CA, Ghaisas N, Kass S, Donnelly S, Basson CT, Watkins HC, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. *J Clin Invest. (1995) 96:1216–20. doi: 10.1172/JCI118154*

115. Lin HY, Chuang CK, Lee CL, Chen MR, Sung KT, Lin H, et al. Familial pseudo-Wolff-Parkinson-White syndrome. *J Pediatr Neurol. (2009) 7:005.

116. Ingwall JS. Transgenic and cardio energetic: new insights into cardiac metabolism. *J Mol Cell Cardiol. (2004) 37:613–23. doi: 10.1016/j.yjmcc.2004.05.020*

117. Arad M, Moskowitz JP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome due to cardiac glycogenosis due to PRKAG2 mutations. *European. (2017) 19:651–9. doi: 10.1007/s00423-017-1347-2*

118. Porto AG, Brun F, Severini GM, Losurdo P, Fabris E, Taylor MRG, et al. Clinical spectrum of PRKAG2 syndrome. *Circ Arrhythm Electrophysiol. (2016) 9:e003121. doi: 10.1161/CIRCEP.115.003121*
